Manufacturer of Controlled Substances; Notice of Application; Wildlife Laboratories Inc., 45378 [2012-18630]
Download as PDF
<![CDATA[
45378
Federal Register / Vol. 77, No. 147 / Tuesday, July 31, 2012 / Notices
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. A redacted nonconfidential version of the document
must also be filed simultaneously with
the any confidential filing. All nonconfidential written submissions will be
available for public inspection at the
Office of the Secretary and on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of sections 201.10 and 210.50 of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.50).
By order of the Commission.
Issued: July 25, 2012.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2012–18596 Filed 7–30–12; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
Notice of Lodging of Consent Decree
Under the Comprehensive
Environmental Response,
Compensation, and Liability Act
Notice is hereby given that on July 25,
2012, a proposed Consent Decree in
United States v. James W. Clark, et al.,
Civil Action No. 08–CV–04158, was
lodged with the United States District
Court for the Northern District of
Illinois.
In this action, the United States
brought claims against Calumet Heat
Treating Company, Thomas G. Cooper,
and Nitrex, Inc. (‘‘Settling Defendants’’)
for response costs associated with the
release or threatened release of
hazardous substances from facilities at
and near the South Green Plating
Superfund Site in Chicago, Illinois
(hereinafter the ‘‘Site’’), pursuant to the
Comprehensive Environmental
Response, Compensation, and Liability
Act, 42 U.S.C. 9601 et seq. (‘‘CERCLA’’).
The proposed Consent Decree requires
Settling Defendants to reimburse the
United States’ past response costs in the
amount of $430,000.00.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either emailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. James W. Clark, et al., Civil
Action No. 08–CV–04158 (N.D. Ill.), D.J.
Ref. No. 90–11–3–09477.
VerDate Mar<15>2010
16:48 Jul 30, 2012
Jkt 226001
During the public comment period,
the Consent Decree may be examined on
the following Department of Justice Web
site: https://www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611 or
by faxing or emailing a request to
Environment and Natural Resources
Division, Environmental Enforcement
Section, fax no. (202) 514–0097, phone
confirmation number (202) 514–5271,
email EESCDCopy.ENRD@usdoj.gov. If
requesting a copy from the Consent
Decree Library, please enclose a check
in the amount of $5.50 for a copy of the
complete Consent Decree (25 cents per
page reproduction cost) payable to the
U.S. Treasury or, if by email or fax,
forward a check in that amount to the
Consent Decree Library at the stated
address.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2012–18517 Filed 7–30–12; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Wildlife Laboratories Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 21, 2012,
Wildlife Laboratories Inc., 1230 W. Ash
Street, Suite D, Windsor, Colorado
80550, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
PO 00000
Frm 00051
Fmt 4703
Sfmt 9990
Springfield, Virginia 22152; and must be
filed no later than October 1, 2012.
Dated: April 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18630 Filed 7–30–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (NIJ) Docket No. 1600]
Guidelines for Cases Requiring OnScene Death Investigation
AGENCY:
National Institute of Justice,
Justice.
Notice and request for
comments.
ACTION:
In an effort to obtain
comments from interested parties, the
U.S. Department of Justice, Office of
Justice Programs, National Institute of
Justice, Scientific Working Group for
Medicolegal Death Investigation will
make available to the general public a
draft document entitled, ‘‘Guidelines for
Cases Requiring On-Scene Death
Investigation’’. The opportunity to
provide comments on this document is
open to coroner/medical examiner office
representatives, law enforcement
agencies, organizations, and all other
stakeholders and interested parties.
Those individuals wishing to obtain and
provide comments on the draft
document under consideration are
directed to the following link: https://
swgmdi.org/index.php?option=com_
content&view=article&id=85&
Itemid=102.
SUMMARY:
Comments must be received on
or before August 22, 2012.
DATES:
FOR FURTHER INFORMATION CONTACT:
Patricia Kashtan, by telephone at 202–
353–1856 [Note: this is not a toll-free
telephone number], or by email at
Patricia.Kashtan@usdoj.gov.
John Laub,
Director, National Institute of Justice.
[FR Doc. 2012–18623 Filed 7–30–12; 8:45 am]
BILLING CODE 4410–18–P
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 77, Number 147 (Tuesday, July 31, 2012)]
[Notices]
[Page 45378]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-18630]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Wildlife Laboratories Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 21, 2012, Wildlife
Laboratories Inc., 1230 W. Ash Street, Suite D, Windsor, Colorado
80550, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of
Carfentanil (9743), a basic class of controlled substance listed in
schedule II.
The company plans to manufacture the above listed controlled
substance for sale to veterinary pharmacies, zoos, and for other animal
and wildlife applications.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance, may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 1, 2012.
Dated: April 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-18630 Filed 7-30-12; 8:45 am]
BILLING CODE 4410-09-P
